admin, Author at Invivoscribe

About admin

This author has not yet filled in any details.
So far admin has created 66 blog entries.

Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer.

admin2020-09-08T16:35:09+00:00September 8th, 2020|Categories: Press Releases|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

admin2020-11-25T18:05:35+00:00August 27th, 2020|Categories: Publications|Tags: B cell lymphoma, Follicular Lymphoma, Follicular Neoplasia|

VIEW PUBLICATION ⟶

> Read More

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

admin2020-09-08T16:28:40+00:00August 23rd, 2020|Categories: Featured Publications, Newsfeed, Publications|Tags: CLL, IgHV, Targeted Deep Sequencing|

VIEW PUBLICATION ⟶

> Read More

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

admin2020-11-25T18:18:47+00:00July 22nd, 2020|Categories: Publications|Tags: Baseline VDJ Clonotype Detection, LymphoTrack Assays, MRD, Multiple Myeloma, Targeted NGS Assay, Targeted Sequencing|

VIEW PUBLICATION ⟶

> Read More

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia

admin2020-07-14T15:00:54+00:00July 14th, 2020|Categories: Press Releases|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

> Read More

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

admin2020-05-19T16:22:45+00:00May 19th, 2020|Categories: Press Releases|Tags: 3500xL Dx Genetic Analyzer, Acute Myelogenous Leukemia, Acute Myeloid Leukemia, AML, Analysis Software, Commercial Companion Diagnostics, Companion Diagnostics, D835, FDA Approval, FLT3 mut + AML Patients, FLT3 Mutation Test, Gilteritinib Fumarate, I836, In vitro Diagnostic Test, Internal Tandem Duplication, Invivoscribe, ITD, IVD Kit, LabPMM, LeukoStrat® CDx FLT3 Mutation Assay, Midostaurin, PCR-Based, Precision Diagnostics, Quizartinib, Quizartinib Hydrochloride, Relapsed/Refractory, Rydapt®, TKD, Tyrosine Kinase Domain, United States, US, Xospata®|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

> Read More

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-27T18:13:43+00:00May 15th, 2020|Categories: Events, Upcoming Events|

VIRTUAL
May 29 – 30, 2020

> Read More

Invivoscribe to Exhibit at 25th EHA Annual Congress

admin2020-05-27T18:11:58+00:00May 15th, 2020|Categories: Events, Upcoming Events|

VIRTUAL
June 11 – 14, 2020

> Read More

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

admin2020-05-12T17:03:17+00:00May 12th, 2020|Categories: Press Releases|Tags: ADMIRAL, AML, Astellas, Australia, CE-Marked, China, Clinical Trials, Companion Diagnostics, Europe, FLT3 biomarker, Germany, gilteritinib, Invivoscribe, Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd., ITD, Japan, LabPMM, LeukoStrat® CDx FLT3 Mutation Assay, NMPA, QuANTUM-R, RATIFY, refractory FLT3-mutated AML, relapsed FLT3-mutated AML., Rydapt®, Shanghai, Switzerland, TKD, United States, VANFLYTA®, Xospata®|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

> Read More

Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program

admin2020-06-02T18:14:25+00:00April 28th, 2020|Categories: Press Releases|Tags: Coronavirus, COVID-19 Diagnostic Testing, COVID-19 Test, SARS-CoV-2, SARS-CoV-2 Antibody, SARS-CoV-2 Vaccine|

⟵ PRESS RELEASES PRESS RELEASE SAN DIEGO, [...]

> Read More

Load More Posts

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate
drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 1st, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

About admin

Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer.

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

Invivoscribe to Participate in Virtual ASCO 2020

Invivoscribe to Exhibit at 25th EHA Annual Congress

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 13th, 2020 Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 1st, 2019 Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma

About admin

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

August 13th, 2020
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia

October 1st, 2019
Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma